Abstract: Disclosed are various embodiments for increasing the biotransport characteristics of a psychedelic active ingredient across the mammalian blood-brain barrier. Disclosed are pharmaceutically-acceptable psychedelics that, when administered, convert to an active form in vivo, and act as a 5HT2AR agonist which are useful to treat psychiatric disorders, neurological disorders, degenerative disorders, inflammatory disorders, and symptoms thereof.